MX2023002980A - Terapias de combinación de inhibidores del fgfr. - Google Patents
Terapias de combinación de inhibidores del fgfr.Info
- Publication number
- MX2023002980A MX2023002980A MX2023002980A MX2023002980A MX2023002980A MX 2023002980 A MX2023002980 A MX 2023002980A MX 2023002980 A MX2023002980 A MX 2023002980A MX 2023002980 A MX2023002980 A MX 2023002980A MX 2023002980 A MX2023002980 A MX 2023002980A
- Authority
- MX
- Mexico
- Prior art keywords
- genetic alteration
- patient
- inhibitor
- ccnd1
- egfr
- Prior art date
Links
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 title abstract 4
- 238000002648 combination therapy Methods 0.000 title 1
- 230000004077 genetic alteration Effects 0.000 abstract 16
- 231100000118 genetic alteration Toxicity 0.000 abstract 16
- 102000006311 Cyclin D1 Human genes 0.000 abstract 10
- 108010058546 Cyclin D1 Proteins 0.000 abstract 10
- 102000001301 EGF receptor Human genes 0.000 abstract 8
- 108060006698 EGF receptor Proteins 0.000 abstract 8
- 206010028980 Neoplasm Diseases 0.000 abstract 7
- 201000011510 cancer Diseases 0.000 abstract 7
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 abstract 6
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 abstract 6
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 abstract 5
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 abstract 5
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 5
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 5
- 239000003112 inhibitor Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 5
- 229940125431 BRAF inhibitor Drugs 0.000 abstract 3
- 108091008794 FGF receptors Proteins 0.000 abstract 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 abstract 2
- 229940121647 egfr inhibitor Drugs 0.000 abstract 2
- 230000004083 survival effect Effects 0.000 abstract 2
- 239000012472 biological sample Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078193P | 2020-09-14 | 2020-09-14 | |
| PCT/EP2021/075145 WO2022053697A1 (en) | 2020-09-14 | 2021-09-13 | Fgfr inhibitor combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002980A true MX2023002980A (es) | 2023-06-06 |
Family
ID=77821784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002980A MX2023002980A (es) | 2020-09-14 | 2021-09-13 | Terapias de combinación de inhibidores del fgfr. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230321087A1 (https=) |
| EP (1) | EP4210702A1 (https=) |
| JP (1) | JP2023542296A (https=) |
| KR (1) | KR20230069958A (https=) |
| CN (1) | CN116669763A (https=) |
| AU (1) | AU2021339962A1 (https=) |
| CA (1) | CA3191538A1 (https=) |
| MX (1) | MX2023002980A (https=) |
| TW (1) | TW202228695A (https=) |
| WO (1) | WO2022053697A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202308689A (zh) * | 2021-04-21 | 2023-03-01 | 美商健生生物科技公司 | 高濃度的雙特異性抗體調配物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| WO2005110076A2 (en) | 2004-05-10 | 2005-11-24 | Children's Medical Center Corporation | Braf expression in zebrafish and uses thereof |
| EP3042964A1 (en) | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| BRPI0611375A2 (pt) | 2005-05-23 | 2010-08-31 | Novartis Ag | formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| MX361088B (es) * | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| KR102470456B1 (ko) | 2014-09-26 | 2022-11-23 | 얀센 파마슈티카 엔.브이. | Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용 |
| HUE054848T2 (hu) | 2014-10-13 | 2021-09-28 | Yuhan Corp | Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására |
| EP3277689B1 (en) * | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| MA43416A (fr) * | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| CN110869392A (zh) * | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
| CN111868260B (zh) * | 2017-08-07 | 2025-02-21 | 约翰斯霍普金斯大学 | 用于评估和治疗癌症的方法和材料 |
| EP3898626A1 (en) * | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| MA55486A (fr) * | 2019-03-29 | 2022-02-09 | Janssen Pharmaceutica Nv | Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial |
| WO2020208592A1 (en) * | 2019-04-12 | 2020-10-15 | Dr. Reddy’S Laboratories Limited | Process for preparation of erdafitinib, its purification and amorphous solid dispersion |
| CN111420060B (zh) * | 2020-03-30 | 2022-04-08 | 南方医科大学南方医院 | 一种抗肿瘤的联合用药组合物及其应用 |
-
2021
- 2021-09-13 EP EP21773119.9A patent/EP4210702A1/en active Pending
- 2021-09-13 KR KR1020237012158A patent/KR20230069958A/ko not_active Withdrawn
- 2021-09-13 CA CA3191538A patent/CA3191538A1/en active Pending
- 2021-09-13 AU AU2021339962A patent/AU2021339962A1/en not_active Abandoned
- 2021-09-13 US US18/044,232 patent/US20230321087A1/en active Pending
- 2021-09-13 CN CN202180076145.8A patent/CN116669763A/zh active Pending
- 2021-09-13 MX MX2023002980A patent/MX2023002980A/es unknown
- 2021-09-13 JP JP2023516479A patent/JP2023542296A/ja active Pending
- 2021-09-13 WO PCT/EP2021/075145 patent/WO2022053697A1/en not_active Ceased
- 2021-09-14 TW TW110134269A patent/TW202228695A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202228695A (zh) | 2022-08-01 |
| JP2023542296A (ja) | 2023-10-06 |
| CN116669763A (zh) | 2023-08-29 |
| KR20230069958A (ko) | 2023-05-19 |
| AU2021339962A1 (en) | 2023-05-25 |
| WO2022053697A1 (en) | 2022-03-17 |
| US20230321087A1 (en) | 2023-10-12 |
| CA3191538A1 (en) | 2022-03-17 |
| EP4210702A1 (en) | 2023-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McMahon et al. | Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia | |
| Tarafdar et al. | CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression | |
| PH12022550578A1 (en) | Method for identifying responders to smarca2/4 degraders | |
| Clark et al. | The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells | |
| ECSP17025787A (es) | Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr | |
| WO2019118873A3 (en) | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof | |
| EP4378530A3 (en) | Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody | |
| MXPA05014220A (es) | Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos. | |
| MX2023002980A (es) | Terapias de combinación de inhibidores del fgfr. | |
| Turner et al. | Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial | |
| Zabaleta et al. | Clinical significance of measurable residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) patients (Pts) treated with chimeric antigen receptor (CAR) T cells and T-cell engagers (TCE) | |
| Foerster et al. | Early prediction of treatment response by circulating tumor DNA profiling in patients with diffuse large B-cell lymphoma receiving CAR T-cell Therapy | |
| Le Bras et al. | Breast implant associated-anaplastic large cell lymphoma (BIA-ALCL): The Lymphoma Study Association (LYSA) registry data | |
| Waliany et al. | Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium | |
| Huang et al. | Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia | |
| Rocchi et al. | Ex-vivo drug response profiling for precision medicine approaches in acute myeloid leukemia with the open microwell microfluidic platform | |
| Yates et al. | Next generation sequencing of BRCA1/2 in high grade ovarian tumors expands BRCA defects beyond germline mutations | |
| d’Onofrio | “Noisy Oncology”: Some Caveats in using Gaussian Noise in Mathematical Models of Chemotherapy | |
| Lu et al. | Generalized syringotropic mycosis fungoides responsive to total skin electron beam therapy | |
| Scott et al. | Cell-of-origin assignment in diffuse large B-cell lymphoma determined by gene expression in formalin-fixed paraffin-embedded tissue has prognostic significance independent of IPI and MYC/BCL2 immunohistochemistry | |
| Le Bras et al. | Breast implant associated-anaplastic large cell lymphoma (BIA-ALCL): the French Lymphoma Study Association (LYSA) registry data | |
| Decaudin et al. | Combinations of targeted therapies in human cancers | |
| Staber et al. | Imatinib+/-brentuximab vedotin induces sustained complete remission in chemotherapy-resistant anaplastic large cell lymphoma expressing PDGFR | |
| Winter et al. | A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma | |
| Dean et al. | P3. 13-28 Heterogeneity, Prevalence and Prognostic Significance of PDL1 Expression in Early Resected NSCLC |